Search Results - "Mahgoub, Thamir"

Evaluation of ABT-751, a novel anti-mitotic agent able to overcome multi-drug resistance, in melanoma cells by Mahgoub, Thamir M., Jordan, Emmet J., Mahdi, Amira F., Oettl, Veronika, Huefner, Stefanie, O’Donovan, Norma, Crown, John, Collins, Denis M.

“…Purpose Drug efflux transporter associated multi-drug resistance (MDR) is a potential limitation in the use of taxane chemotherapies for the treatment of…”
Get full text

New era for emerging therapeutic targeting human epidermal growth factor receptor 3 (HER 3) in advanced nonsmall cell lung cancer and metastatic breast cancer by Ahmed, Yasar, Mahgoub, Thamir, Sindi, Maha Al, Berenguer‐Pina, José J.

“…Human epidermal growth factor receptor 3 (HER3) is a member of the transmembrane receptor tyrosine kinase family. Upregulation of HER3 pathway has been…”
Get full text

Predictive biomarkers for dasatinib treatment in melanoma by Eustace, Alex J, Kennedy, Susan, Larkin, Anne-Marie, Mahgoub, Thamir, Tryfonopoulos, Dimitrios, O'Driscoll, Lorraine, Clynes, Martin, Crown, John, O'Donovan, Norma

“…Dasatinib has anti-proliferative and anti-invasive effects in melanoma cell lines. However clinical trials have shown modest activity for dasatinib in…”
Get full text

The impact of the COVID-19 pandemic on oncology clinical trial recruitment in an Irish cancer center by McLaughlin, Ronan Andrew, Madigan, Valerie, O'Grady, Maureen, Mahgoub, Thamir Andrew, Kalachand, Roshni Andrew, Osman, Nemer, Korpanty, Greg, Coate, Linda E.

“…Abstract only e18756 Background: The COVID-19 pandemic has created unprecedented disruptions to cancer clinical trial research across the world due to a…”
Get full text

Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer by Collins, Denis M, Madden, Stephen F, Gaynor, Nicola, AlSultan, Dalal, Le Gal, Marion, Eustace, Alex J, Gately, Kathy A, Hughes, Clare, Davies, Anthony M, Mahgoub, Thamir, Ballot, Jo, Toomey, Sinead, O'Connor, Darran P, Gallagher, William M, Holmes, Frankie A, Espina, Virginia, Liotta, Lance, Hennessy, Bryan T, O'Byrne, Kenneth J, Hasmann, Max, Bossenmaier, Birgit, O'Donovan, Norma, Crown, John

“…Antibody-dependent cell-mediated cytotoxicity (ADCC) is one mechanism of action of the monoclonal antibody (mAb) therapies trastuzumab and pertuzumab. Tyrosine…”
Get full text

Alternative signalling mechanisms to mediate Braf-Inhibitor resistance in isogenic primary and metastatic melanoma by Maguire, Alanna, Walsh, Naomi, O'Donovan, Norma, Mahgoub, Thamir, Crown, John

“…Abstract only…”
Get full text

Trastuzumab (T) and pertuzumab (P)-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) in tyrosine kinase inhibitor (TKI)-treated breast cancer (BC) cell lines by Collins, Denis, O'Donovan, Norma, Mahgoub, Thamir, Gately, Kathy, Hughes, Clare, Davies, Anthony, O'Byrne, Kenneth, Crown, John

“…Abstract only…”
Get full text

CD10−/ALDH− cells are the sole cisplatin-resistant component of a novel ovarian cancer stem cell hierarchy by Ffrench, Brendan, Gasch, Claudia, Hokamp, Karsten, Spillane, Cathy, Blackshields, Gordon, Mahgoub, Thamir Mahmoud, Bates, Mark, Kehoe, Louise, Mooney, Aoibhinn, Doyle, Ronan, Doyle, Brendan, O'Donnell, Dearbhaile, Gleeson, Noreen, Hennessy, Bryan T, Stordal, Britta, O'Riain, Ciaran, Lambkin, Helen, O'Toole, Sharon, O'Leary, John J, Gallagher, Michael F

“…It is long established that tumour-initiating cancer stem cells (CSCs) possess chemoresistant properties. However, little is known of the mechanisms involved,…”
Get full text

Abstract P1-11-09: Five year follow up of a randomized phase II comparison of neo-adjuvant docetaxel, carboplatin, trastuzumab with or without lapatinib in HER-2 positive breast cancer by Crown, John, Collins, Denis M., Eustace, Alex J., Keane, Maccon, Coate, Linda, Kennedy, John, O’Reilly, Seamus, Kelly, Catherine, O’Connor, Miriam, Martin, Michael J., Murphy, Conleth, Duffy, Karen, Walshe, Janice, Mahgoub, Thamir, Gullo, Giuseppe, Moulton, Brian, Alvarez-Iglesias, Alberto, Parker, Imelda, Hennessy, Bryan

“…Abstract Background: The addition of trastuzumab (H) to pre-operative chemotherapy in HER2+ breast cancer (H+BC) increases the rate of pathological complete…”
Get full text

Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours by Browne, Brigid C., Eustace, Alex J., Kennedy, Susan, O’Brien, Neil A., Pedersen, Kasper, McDermott, Martina S. J., Larkin, Annemarie, Ballot, Jo, Mahgoub, Thamir, Sclafani, Francesco, Madden, Stephen, Kennedy, John, Duffy, Michael J., Crown, John, O’Donovan, Norma

“…Insulin-like growth factor-1 receptor (IGF1R) signalling is implicated in resistance to trastuzumab. However, the benefit of co-targeting HER2 and IGF1R has…”
Get full text

Synthesis, characterisation and biological evaluation of N-(ferrocenyl)naphthoyl amino acid esters as anticancer agents by Mooney, Aine, Corry, Alan J, Ní Ruairc, Cliodhna, Mahgoub, Thamir, O'Sullivan, Dermot, O'Donovan, Norma, Crown, John, Varughese, Sunil, Draper, Sylvia M, Rai, Dilip K, Kenny, Peter T M

“…A series of N-(ferrocenyl)naphthoyl amino acid esters 5-18 has been prepared by coupling ferrocenyl naphthoic acids 3-4 to alpha-amino acids and linear amino…”
Get more information

Erratum to: Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours by Browne, Brigid C., Eustace, Alex J., Kennedy, Susan, O’Brien, Neil A., Pedersen, Kasper, McDermott, Martina S. J., Larkin, Annemarie, Ballot, Jo, Mahgoub, Thamir, Sclafani, Francesco, Madden, Stephen, Kennedy, John, Duffy, Michael J., Crown, John, O’Donovan, Norma

Get full text